Li, Nanxin <br/><br/>
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.  [electronic resource] 

 -  Current medical research and opinion  2016 
 - 385-94 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-4877 
<br/><br/><label>Standard No.: </label>10.1185/03007995.2015.1130691  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Capecitabine--administration & dosage<br/>Everolimus--administration & dosage<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Postmenopause<br/>Proportional Hazards Models<br/>Receptor, ErbB-2<br/>Retrospective Studies